Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

J&J agrees to pay nearly five times its original offer Deal follows appeals court rebuke of J&J's "Texas two-step" bankruptcy Settlement with cancer victims still faces legal obstacles April 4 ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...